New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
08:38 EDTENTAEnanta Pharmaceuticals ABT-493 has potential, says JMP Securities
After examining data on Enanta's protease inhibitor, ABT-493. JMP Securities is encouraged by the drug's potential, as the firm thinks it can be competitive in the HCV space. The firm reiterates a $50 price target and Outperform rating on the shares.
News For ENTA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2014
08:07 EDTENTAEnanta regains full rights to EDP-239 for Hep C virus from Novartis
Subscribe for More Information
September 18, 2014
07:51 EDTENTAAlan Dworsky reports 5.4% passive stake in Enanta
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use